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Mitochondrial dysfunction is a common cause of
peripheral neuropathy. Much effort has been
devoted to examining the role played by neuronal/
axonal mitochondria, but how mitochondrial deficits
in peripheral nerve glia (Schwann cells [SCs]) con-
tribute to peripheral nerve diseases remains unclear.
Here, we investigate a mouse model of peripheral
neuropathy secondary to SC mitochondrial dysfunc-
tion (Tfam-SCKOs). We show that disruption of SC
mitochondria activates a maladaptive integrated
stress response (ISR) through the actions of heme-
regulated inhibitor (HRI) kinase, and causes a shift
in lipid metabolism away from fatty acid synthesis
toward oxidation. These alterations in SC lipid
metabolism result in depletion of important myelin
lipid components as well as in accumulation of
acylcarnitines (ACs), an intermediate of fatty acid
b-oxidation. Importantly, we show that ACs are
released from SCs and induce axonal degeneration.
A maladaptive ISR as well as altered SC lipid metab-
olism are thus underlying pathological mechanisms
in mitochondria-related peripheral neuropathies.
INTRODUCTION
Mitochondrial metabolic irregularities are a common culprit in
diverse neurodegenerative diseases and are key pathological
contributors to peripheral neuropathy. Mitochondrial dysfunc-
tion is thought to be largely responsible for the peripheral nerve
deficits that afflict large numbers of people with diabetes and
can lead to incapacitating pain, sensory loss, and debilitating
muscle weakness (Fernyhough et al., 2010). Similarly, a number
of mutations in mitochondrial proteins have now been identified
as the cause of several forms of inherited neuropathies known as
Charcot-Marie-Tooth (CMT) (Niemann et al., 2006). The need
to elucidate the manner in which mitochondrial dysfunction
underlies the progression of peripheral nerve disease is thus886 Neuron 77, 886–898, March 6, 2013 ª2013 Elsevier Inc.well appreciated, and to date, much effort has been devoted to
clarifying the role played by neuronal/axonal mitochondria in
peripheral neuropathies (Baloh, 2008).
Glial cells, however, are involved in virtually every aspect of
nervous system function (Barres, 2008). Hence, it is increasingly
being recognized that glia influence neurodegenerative diseases
that were traditionally thought to be neuron autonomous (e.g.,
amyotrophic lateral sclerosis; Ilieva et al., 2009). In the peripheral
nervous system, glial cells known as Schwann cells (SCs) criti-
cally support the long-term preservation and function of all
peripheral nerve axons, as well as their repair after damage
(Nave and Trapp, 2008). Interestingly, abnormal mitochondria
in the nerves of patients with neuropathy often localize to SCs
(Schro¨der, 1993; Kalichman et al., 1998). Mitochondrial dysfunc-
tion specifically in SCs is thus likely to be a critical mediator of
nerve pathology, and understanding how mitochondrial deficits
in these glia contribute to disease progression could facilitate
development of novel treatments for peripheral neuropathies.
To directly interrogate the contribution of SC mitochondrial
dysfunction to peripheral nerve disease, we recently generated
mice (Tfam-SCKOs) with disrupted mitochondrial metabolism
exclusively in SCs (Viader et al., 2011). Remarkably, these
mice recapitulated key pathological features of human neuropa-
thies, making them a valuable model in which to examine the
pathological processes that drive mitochondrial peripheral
nerve disorders. In the present work, we use this model of
neuropathy to demonstrate that SC mitochondrial dysfunction
contributes to disease progression by activating a maladaptive
integrated stress response (ISR) through the actions of heme-
regulated inhibitor (HRI) kinase. Moreover, we also identify
a mitochondrial-dysfunction-induced shift in SC lipid metabo-
lism away from new lipid synthesis toward increased fatty acid
oxidation. This metabolic alteration results in early depletion of
myelin lipid components as well as a large accumulation of
acylcarnitine (AC) lipid intermediates. Importantly, we show
that ACs are released fromSCs and induce axonal degeneration.
Activation of a maladaptive ISR and altered SC lipid metabolism
resulting in toxic accumulation of lipid intermediates are thus
underlying mechanisms of axonal degeneration and demyelina-
tion in mitochondrial peripheral neuropathies and constitute
potentially important therapeutic targets.
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Tfam-SCKO Mice: A Model of Peripheral Neuropathy
Secondary to SC Mitochondrial Dysfunction
With the goal of understanding whether SCmitochondrial abnor-
malities affect axonal survival and contribute to peripheral nerve
diseases, we used the tissue-specific deletion of the mitochon-
drial transcription factor A gene (Tfam) to generate mice with
impaired mitochondrial metabolism exclusively in SCs (Tfam-
SCKOs; Viader et al., 2011). TFAM is a nuclear-encoded
mitochondrial protein that is essential for the maintenance, tran-
scription, and replication of mitochondrial DNA (mtDNA; Larsson
et al., 1998; Ekstrand et al., 2004). Given that the mitochondrial
genome encodes 13 subunits that are necessary components
of complexes I, III, IV, and V of the electron transport chain,
excision of Tfam from a tissue of interest results in severe
mtDNA depletion and mitochondrial respiratory chain deficiency
(Larsson et al., 1998; Silva et al., 2000; Viader et al., 2011). This
makes the tissue-specific deletion of Tfam an effective way
to induce mitochondrial dysfunction in a selected population
of cells.
As detailed elsewhere (Viader et al., 2011), we achieved highly
selective and efficient excision of Tfam from SCs by mating mice
with loxP-flanked Tfam alleles (TfamloxP; Larsson et al., 1998) to
mice that express cre-recombinase in bothmyelinating and non-
myelinating SCs via the myelin protein zero (P0) promoter (Feltri
et al., 1999). Following the SC-specific deletion of Tfam, and
consistent with the essential role of this protein in the replica-
tion/transcription of mtDNA (Larsson et al., 1998; Ekstrand
et al., 2004), we observed severe depletion of mtDNA and the
transcripts it encodes (e.g., mt-ND2 and mt-Cox1) in 2-month-
old Tfam-SCKO nerves compared with controls (Figure S1A
available online; Viader et al., 2011). This depletion resulted in
the inhibition of mitochondrial respiratory chain enzymes and
overall mitochondrial respiration in the nerves of Tfam-SCKO
mice (Figures S1B and S1C; Viader et al., 2011). Accordingly,
COX enzymatic staining, which reflects respiratory chain activity
in individual cells, showed reduced staining intensity in the cell
bodies of SCs in Tfam-SCKO sciatic nerves (Figure S1D). More-
over, electron microscopic examination of Tfam-SCKO nerves
revealed many morphologically abnormal mitochondria in SCs
as early as 1 month of age (Figure S1E; Viader et al., 2011),
thus confirming that SC-specific deletion of Tfam resulted in
mice with disrupted mitochondrial metabolism in peripheral
nerve glia.
Interestingly, induction of SC-specific mitochondrial dysfunc-
tion did not affect SC survival (Viader et al., 2011). SC-specific
mitochondrial deficits instead resulted in a severe, progressive
peripheral neuropathy characterized by extensive axonal degen-
eration that recapitulated critical features of human neuropathy.
As previously reported for polyneuropathies associated with
diabetes (Kennedy et al., 1996), Tfam-SCKO nerves displayed
early abnormalities and preferential loss of small unmyelinated
C fibers (starting at 1–2 months of age; Figure 1A; Viader et al.,
2011). This was followed by the degeneration of large-caliber
myelinated axons (starting at 3–4 months of age; Figures 1B
and 1C; Viader et al., 2011). Extensive demyelination was
apparent at late stages of the disease (Figure 1B). Consistentwith this nerve pathology, Tfam-SCKO mice developed pro-
gressive distal weakness and sensory deficits (Viader et al.,
2011), which are common symptoms in patients with peripheral
neuropathy. Therefore, Tfam-SCKO mice are a SC-specific
metabolic mutant that recapitulates pathological aspects of
human peripheral neuropathies.
Energy Depletion Does Not Drive Nerve Pathology
in Tfam-SCKO Mice
Having established the utility of the Tfam-SCKOmousemodel for
understanding and potentially treating peripheral neuropathies,
we explored causal mechanisms of the nerve pathology in these
mice. Importantly, we focused our analysis on 2-month-old
Tfam-SCKOs. At this age, SC mitochondrial function is already
disrupted (Figures S1A–S1E), yet Tfam-SCKO nerves display
only very limited, early pathological changes that are largely
confined to unmyelinated fibers (Figures 1A–1C; Viader et al.,
2011). By using pre-/early-pathological Tfam-SCKO mice, we
ensured that the disease mechanisms we identified were drivers
of subsequent nerve abnormalities rather than simply a reflection
of them. All experiments described below were carried out on
2-month-old Tfam-SCKO mice in the early (prepathological)
stage of the disorder.
We first determined the energy status of Ctrl and Tfam-defi-
cient SCs because clinical deficits in diseases associated with
mitochondrial dysfunction are often assumed to be directly
related to depletion of cellular energy levels. Surprisingly,
measurement of nerve adenylate pools and determination of
the adenylate energy charge (EC), an index used to measure
cellular energy status (see Experimental Procedures; Atkinson,
1968), revealed only a very slight energy reduction (z8%) in
Tfam-SCKO nerves (Ctrl, EC = 0.812 ± 0.009; Tfam-SCKO,
EC = 0.747 ± 0.008; p < 0.001; Figure 1D). Increased mitochon-
drial content and glycolytic activity in Tfam-deficient SCs
(Figures S1F–S1H), two metabolic adaptations that often follow
mitochondrial deficits, likely account for the relative preservation
of energy levels in Tfam-SCKO nerves.
To further examine the energy status of Tfam-deficient SCs,
we next assessed the phosphorylation of the cellular energy
sensor AMP-activated protein kinase (AMPK). Phosphorylation
at Thr172 activates AMPK and is induced by increases in the
cellular AMP:ATP ratio (Hardie et al., 2012), making it a good
indicator of reductions in cellular energy levels. We observed
no difference in the level of AMPK phosphorylation between
2-month-old Ctrl and Tfam-SCKO nerves (Figure 1E). Together,
these results indicate that Tfam-deficient SCs do not experience
energy depletion to an extent that is likely to be responsible for
the nerve pathology observed in these mice.
Mitochondrial Dysfunction in SCs Activates
a Maladaptive ISR
In an attempt to identify other potential disease-causing pro-
cesses, we carried out gene-expression profiling of 2-month-
old Ctrl and Tfam-SCKO nerves. This analysis uncovered the
upregulation of a number of genes activated by the ISR (e.g.,
Ddit3/Chop, Asns, Mthfd2, and Trib3) in SCs with disrupted
mitochondrial metabolism (Table S1). The ISR is a conserved
gene-expression program that helps cells withstand diverseNeuron 77, 886–898, March 6, 2013 ª2013 Elsevier Inc. 887
Figure 1. SC Mitochondrial Dysfunction Induces a Progressive,
Degenerative Peripheral Neuropathy that Is Not Directly Linked
to Energy Depletion
(A) Electron micrographs of 1-month-old Ctrl and Tfam-SCKO sciatic nerve
cross-sections depicting early structural abnormalities of Remak bundles (SC
surrounding multiple unmyelinated axons; arrowheads) and degeneration of
unmyelinated axons (asterisk). A, axon; C, SC cytoplasm; N, SC nucleus. Scale
bar, 500 nm.
(B and C) Toluidine-blue-stained plastic sections of Tfam-SCKO and Ctrl
sciatic nerve cross-sections (B) and quantification of the total number of
myelinated profiles per nerve (C) at different ages showprominent, progressive
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through the phosphorylation of the translation initiation factor
2a (eIF2a; Dalton et al., 2012). Importantly, previous work exam-
ining neuropathy models induced by mutations in structural
myelin proteins showed that activation of the ISR is particularly
maladaptive to SCs and can cause nerve pathology (Pennuto
et al., 2008). This suggests that the ISR is a likely driver of disease
progression in Tfam-SCKOmice, which prompted us to examine
the activation of this pathway in more detail.
We confirmed ISR activation in 2-month-old Tfam-SCKOs
nerves by verifying the upregulation of ISR target genes using
quantitative RT-PCR (qRT-PCR; Figure 2A). Western blot
analysis also showed hyperphosphorylation of eIF2a in Tfam-
SCKO nerves compared with controls (Figure 2B). Moreover,
we found that pharmacological inhibition of mitochondria in
cultured SCs (e.g., using CCCP, antimycin, or oligomycin) also
led to induction of ISR target genes (Figure 2C) and increased
phosphorylation of eIF2a (Figure 2D). Themaladaptive activation
of the ISR downstream of eIF2a phosphorylation in Tfam-
SCKO nerves is thus a primary effect of mitochondrial dysfunc-
tion in SCs.
Mitochondrial Dysfunction-Induced ISR Activation in
SCs Is Mediated by HRI and Is Independent of ER Stress
In models of human neuropathy induced by mutations in myelin
proteins, ISR activation is associated with endoplasmic retic-
ulum (ER) stress or an unfolded protein response (UPR; Pennuto
et al., 2008). Thus, we next sought to determine whether similar
mechanisms were responsible for induction of the ISR in Tfam-
SCKO nerves following respiratory chain deficiency. We found,
however, that PKR-like ER kinase (PERK), the primary ER-stress
sensor for ISR induction (Walter and Ron, 2011), was not acti-
vated in 2-month-old Tfam-SCKO nerves (as determined by its
phosphorylation; Figure 3A). In agreement with this, expression
of the UPR-induced molecular chaperon BiP/Grp78 was also
not elevated in Tfam-SCKO nerves (Figure 3A). IRE-1, a second
ER-stress sensor normally activated by the UPR (Walter and
Ron, 2011), was also not engaged in either Tfam-SCKO nerves
or cultured SCs treated with mitochondrial inhibitors (as
determined by splicing of the IRE-1 target Xbp-1; Figure 3B).
Therefore, mitochondrial electron transport chain deficits in
SCs activate ISR through a process that is distinct from its
activation by ER stress.degeneration of large-caliber myelinated axons and demyelination starting at
3–4 months of age. Arrowheads (B) indicate axons surrounded by unusually
thin myelin, a sign of demyelination. Arrow in (C) indicates the point in the
progression of the pathology for all mice used in later experiments; note that at
this age, nerves display only limited, early pathological changes with minimal
axon loss and demyelination. N = 4 mice per genotype at each age. Error bars
represent SEM; *p < 0.01. Scale bar, 25 mm.
(D) EC in 2-month-old Tfam-SCKO nerves shows only a slight decrease in the
energy levels of Tfam-deficient SCs compared with Ctrl nerves. N = 8mice per
genotype. Error bars represent SEM; *p < 0.01. See also Figure S1.
(E) Immunoblot analysis and quantification of band intensity reveals no
increase in the phosphorylation (activation) of the energy sensor AMPK in
2-month-old Tfam-SCKOnerves, indicating that energy depletion is an unlikely
driver of nerve pathology in these mice. N = 4 mice per genotype. Error bars
represent SEM. See also Figure S1.
Figure 2. SC Mitochondrial Dysfunction Activates a Maladaptive ISR
(A) SC mitochondrial dysfunction upregulates the expression of ISR target genes in 2-month-old Tfam-SCKO nerves compared with Ctrl as measured by
qRT-PCR. Atf4, activating transcription factor 4; Ddit3, DNA-damage inducible transcript 3; Asns, asparagine synthetase; Mthfd2, methylenetetrahydrofolate
dehydrogenase; Trib3, tribbles homolog 3. N = 5 mice per genotype. Error bars represent SEM; *p < 0.05.
(B) Immunoblot analysis shows increased phosphorylation of eIF2a in 2-month-old Tfam-SCKO versus Ctrl nerves, confirming the activation of the ISR.
(C) Inhibition of mitochondrial respiration in cultured SCs with mitochondrial inhibitors upregulates the expression of ISR target genes as measured by qRT-PCR.
N = duplicate wells from three independent experiments. Error bars represent SEM; *p < 0.05.
(D) Immunoblot analysis shows that application of the mitochondrial inhibitor CCCP to cultured SCs increases phosphorylation of eIF2a, indicating that inhibition
of the mitochondrial electron transport chain activates the ISR.
See also Table S1.
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eIF2a and downstream ISR activation in Tfam-SCKO mice, we
attempted to identify the kinase responsible for these processes
following mitochondrial dysfunction. We focused on general
control nondepressible-2 kinase (GCN2), protein kinase RNA-
activated (PKR), and HRI, three additional kinases that induce
eIF2a phosphorylation in response to amino acid deprivation,
viral infection, or iron deficiency, respectively (Dalton et al.,
2012). We found that only knockdown of HRI was sufficient
to prevent eIF2a phosphorylation in cultured cells following
treatment with the mitochondrial inhibitor CCCP (Figures 3C
and 3E). Accordingly, the subsequent eIF2a phosphorylation-
dependent induction of the ISR mediator DDIT3/Chop was also
prevented by HRI knockdown (Figure 3E). HRI activity is tradi-
tionally thought to be triggered by iron deficiency (Dalton et al.,
2012), and our observations now link the kinase activity of HRI
to defects in mitochondrial respiration. The maladaptive activa-
tion of the ISR in SCs through distinct eIF2a kinases that respond
to diverse stressors (e.g., HRI to mitochondrial dysfunction, and
PERK to ER stress) may thus be a central pathological mecha-
nism common to multiple types of peripheral neuropathy.
Mitochondrial Dysfunction Alters SC Lipid Metabolism
Homeostasis
The diverse etiology of mitochondrial neuropathies modeled by
Tfam-SCKO mice is consistent with the notion that the interac-
tions of multiple pathological processes ultimately drive disease
progression. Therefore, we mined genes differentially expressed
in 2-month-old Tfam-SCKO nerves to search for additional
disease-causing processes. Interestingly, we found that lipid-
related metabolic pathways were overrepresented in this set of
genes (Figure 4A), suggesting alterations in SC lipid metabolism
secondary to mitochondrial derangements. Indeed, qRT-PCRconfirmed that a number of genes that are critically involved in
lipid synthesis were downregulated in Tfam-deficient SCs,
including fatty acid synthase (Fasn) and 3-hydroxy-3-methyl-
glutaryl-coenzyme A (CoA) reductase (Hmgcr; Figure 4B). More-
over, we found that acetyl-CoA carboxylase (ACC) phosphoryla-
tion, which inhibits the activity of this enzyme (Figure 4C), was
increased 3-fold in 2-month-old Tfam-SCKO nerves (Figures
4D and 4E). ACC supplies malonyl-CoA, which is required for
lipid biosynthesis, thereby regulating the balance between lipid
synthesis and oxidation (Figure 4C; Barber et al., 2005).
Increased phosphorylation of ACC in Tfam-SCKO nerves and
decreased expression of lipid synthetic genes are consistent
with a shift in lipid metabolism away from new lipid synthesis
and toward increased lipid oxidation. Given the central role of
lipids in the normal biology of SCs (e.g., myelin formation; Chrast
et al., 2011), this remodeling of SC lipid metabolism following
mitochondrial deficits could be a second disease-causing
process that is central to the pathology of Tfam-SCKO mice.
Mitochondrial Dysfunction-Induced Remodeling
of SC Lipid Metabolism Depletes Key Myelin Lipid
Components and Disrupts Axon–SC Interactions
To examine in more detail the implications of mitochondrial
dysfunction-induced lipid changes for the pathology observed
in Tfam-SCKO nerves, we performed a comprehensive analysis
of the lipid composition of 2-month-old Ctrl and Tfam-SCKO
nerves using multidimensional mass-spectrometry-based
shotgun lipidomics (Yang et al., 2009). Among all the different
lipid classes examined, cerebrosides (CBs) and sulfatides (STs)
were the only lipid classes with reduced levels (30% and 40%
reductions, respectively) in 2-month-old Tfam-SCKO nerves
(Figures 5A and 5B). In peripheral nerves, CBs and STs are
almost exclusively produced by SCs and are particularlyNeuron 77, 886–898, March 6, 2013 ª2013 Elsevier Inc. 889
Figure 3. Mitochondrial Dysfunction-Induced ISR Activation in SCs
Is Mediated by HRI Kinase Independently of ER Stress
(A) Immunoblot analysis of the phosphorylation (activation) status of the
ER-stress sensor PERK and the UPR-induced molecular chaperone BiP/
Grp78 in 2-month-old Ctrl and Tfam-SCKO nerves (three separate mice per
genotype) shows no differences, indicating that ISR activation following SC
mitochondrial deficits does not involve ER stress. Tunicamycin treatment of
sciatic nerves cultured as explants serves as a positive control for ER stress.
Tun, tunicamycin; Veh, vehicle.
(B) Gel showing the absence of Xbp-1 splicing downstream of the activation
of the ER-stress sensor Ire-1 in 2-month-old Tfam-SCKO nerves, or SCs
treated with mitochondrial inhibitors, confirms that ISR activation induced
by mitochondrial derangement is independent of ER stress. Tunicamycin
treatment of cultured SCs or sciatic nerves cultured as explants serves as
a positive control for ER stress.
(C) Immunoblot analysis of eIF2a phosphorylation in 3T3 cells expressing
shRNA to the indicated eIF2a kinases (HRI, PKR, PERK, and GCN2) that were
treated for 3 hr with 5 mM CCCP to inhibit mitochondrial respiration. Knock-
down of HRI (but not of GCN2, PKR, or PERK) is sufficient to prevent eIF2a
phosphorylation following inhibition of mitochondrial respiration, indicating the
specific role of HRI in this process.
(D) Quantification of the immunoblot as shown in (C) by densitometry. N = 3
independent experiments. Error bars represent SEM; *p < 0.05.
(E) Immunoblot analysis of the induction the ISR mediator DDIT3/CHOP 6 hr
after inhibition of mitochondrial respiration with 5 mM CCCP in 3T3 cells in
which expression of the indicated eIF2a kinase (HRI, PKR, PERK, or GCN2)
was knocked down using shRNA. Knockdown of HRI (but not of GCN2, PKR,
or PERK) is sufficient to prevent DDIT3/CHOP induction downstream of eIF2a
phosphorylation following inhibition of mitochondrial respiration.
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all lipid content in peripheral myelin (Garbay et al., 2000). The
depletion of these two important myelin glycosphingolipids
from Tfam-SCKO nerves is therefore in agreement with our
observations suggesting that mitochondrial dysfunction in SCs
results in a metabolic shift away from lipid biosynthesis.
Of importance for the pathology of Tfam-SCKO mice, ST and
CB depletion disrupts saltatory conduction of action potentials
and interferes with the maintenance of SC–axon contacts and
ion channel clustering around the nodes of Ranvier (Dupree
et al., 1998; Hoshi et al., 2007). In agreement with these reports,
immunostaining of 2-month-old Tfam-SCKO nerves showed
normal nodal clustering of voltage-gated sodium channels
(Nav1.6; Figure 5C) but aberrant localization or loss of
voltage-gated potassium channel clusters (Kv1.2) in the juxta-
paranodal axolemma (Figures 5D and 5E). This abnormal clus-
tering of ion channels is likely responsible for the reduced nerve
conduction velocity (NCV) in 2-month-old Tfam-SCKO mice
(NCV m/s, Ctrl = 24 ± 0.7, Tfam-SCKO = 15.7 ± 0.7; p <
0.05) and is indicative of disrupted axon–SC interactions.
In fact, electron microscopic analysis of 2-month-old Tfam-
SCKO nerves revealed enlarged nodal gaps (Figure 5F) as
well as a significant number of axons that appeared to have
pulled away from their myelin ensheathments (Figure 5G),
both of which reflect abnormal axon–glia contacts. Similar
structural abnormalities were not present in 1-month-old
Tfam-SCKO mice (Figures S2C–S2E) in which nerve ST and
CB content was still equivalent to that of Ctrl mice (Figures
S2A and S2B).
Besides disrupting axon–SC interactions, the reduction of
myelin lipid components induced by mitochondrial dysfunction
may also contribute to the prominent demyelinating phenotype
apparent in late stages of the disease (at >4 months of age)
in Tfam-SCKO mice (Figure 1B; Viader et al., 2011). This is
supported by the observation that depletion of STs and CBs
preceded extensive demyelination (g-ratio at 2 months of age,
axon area/fiber, Ctrl = 0.645 ± 0.008, Tfam-SCKO = 0.647 ±
0.006; Figures 1B and 1C) or changes in expression of myelin
proteins (e.g., myelin basic protein [MBP]) in 2-month-old
Tfam-SCKO nerves (Figures 5H and 5I). Depletion of myelin lipid
components following respiratory-chain-deficiency-induced
remodeling of SC lipid metabolism is thus a key driver of
pathology in mitochondrial neuropathies.
Accumulation of Toxic Lipid Oxidation Intermediates
Characterizes the Mitochondrial-Dysfunction-Induced
Remodeling of SC Lipid Metabolism
The most prominent alteration in lipid composition in 2-month-
old Tfam-SCKO nerves, however, was a 25-fold increase in AC
species (Figure 6A). This increase affected most long-chain
ACs, with the levels of some species being hundreds of times
higher in Tfam-SCKO than in Ctrl nerves (Figures 6B, S3C, and
S3D). ACs are intermediates in transporting fatty acyl groups
across the mitochondrial membrane, which is required for these
groups to undergo fatty acid b-oxidation, an important source of
cellular energy and anabolic metabolites (Figure 6C; Houten and
Wanders, 2010). Increased AC levels in Tfam-SCKO nerves,
therefore, support our previous observations suggesting a shift
Figure 4. SC Mitochondrial Dysfunction
Causes a Shift in Lipid Metabolism away
from Lipid Biosynthesis and toward Fatty
Acid Oxidation
(A) Differentially expressedmRNAs in 2-month-old
Tfam-SCKO nerves as determined by microarray
analysis are enriched for genes involved in lipid
metabolism pathways. The ten pathways with
the most significant enrichment among differen-
tially expressed genes in Tfam-SCKO nerves are
shown.
(B) qRT-PCR analysis confirms that a number
of lipid-synthesis-related enzymes are down-
regulated in 2-month-old Tfam-SCKO versus Ctrl
nerves. Srebp1, sterol regulatory element binding
transcription factor 1; Acly, ATP citrate lyase;
Acc2, ACC beta (primarily localized to mitochon-
dria). N = 5 mice per genotype. Error bars repre-
sent SEM; *p < 0.05.
(C) Diagram depicting the regulation by ACC of
the balance between fatty acid synthesis and
oxidation, and how it is altered by ACC’s phos-
phorylation status.
(D and E) Immunoblot analysis (D) and quantifi-
cation of band intensity (E) show increased phos-
phorylation of ACC in 2-month-old Tfam-SCKO
nerves. Phosphorylation inhibits this central
regulator of the balance between lipid synthesis
and oxidation, indicating (together with gene-
expression results) a shift in lipid metabolism away
from new lipid synthesis and toward increased
lipid oxidation in SC following mitochondrial
dysfunction. N = 4 mice per genotype. Error bars
represent SEM; *p < 0.05.
See also Table S1.
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chondrial deficits (Figure 4).
The severity of the AC buildup in 2-month-old Tfam-SCKO
nerves, however, indicates that the increased shunting of lipids
toward b-oxidation was accompanied by a decrease in the ability
of SCs to oxidize them. The large presence of hydroxy-ACs (Fig-
ure S3E) and the reduced NAD+/NADH ratio in Tfam-SCKO
nerves (Figure S3F) indeed suggest the inhibition of the rate-
determining step in b-oxidation of fatty acids. This step is cata-
lyzed by 3-hydroxyacyl CoA dehydrogenase, which converts
b-hydroxy-acyl-CoA to keto-acyl-CoA (Figure 6C). Inhibition of
this NAD+-dependent step of b-oxidation (by a decreased
NAD+/NADH ratio) leads to accumulation of the transient inter-
mediate 3-hydroxy-acyl-CoA, which can then be converted to
hydroxy-ACs (Su et al., 2005).
Note that although the buildup of ACs peaked at 2 months
of age in Tam-SCKO mice, it was already detectable at 1 month
of age (total AC content nmol/mg, Ctrl = 0.58 ± 0.01, Tfam-
SCKO = 2.41 ± 0.22, p > 0.01; Figures S3A and S3B). AC accu-
mulation thus preceded all other lipid abnormalities in Tfam-
SCKO nerves and its increase coincided with worsening axonal
pathology in these mice. This timing, together with evidence that
high levels of ACs can be toxic, indicates that accumulation of
ACs in Tfam-SCKO nerves is a likely contributor to the neu-
ropathy present in these mice. In fact, genetic diseases that
inhibit fatty acid b-oxidation and lead to accumulation of ACsoften present with severe forms of peripheral neuropathy
(Schaefer et al., 1996; Tyni and Pihko, 1999).
ACs Can Be Released from SCs and Cause Axonal
Toxicity
Given the dramatic increase in AC concentration in Tfam-SCKO
nerves, we examined the possibility that ACs cause the axonal
degeneration observed in Tfam-SCKO mice. This amphiphilic
metabolite adversely alters the properties of membranes and
ion channels with devastating effects (Yamada et al., 2000).
Since ACs can cross the plasma membrane (Houten and
Wanders, 2010) and SCs are intimately associated with axons
in peripheral nerves, we hypothesized that release of ACs from
SCs onto the surrounding axons could alter axonal membrane
properties and ion homeostasis, and contribute to the severe
axon degeneration phenotype in Tfam-SCKO nerves as well as
in neuropathies that present with prominent axonal loss.
To test this hypothesis, we first examined whether long-
chain ACs are released from SCs onto surrounding axons.
Two-month-old Ctrl and Tfam-SCKO nerves were cultured as
explants for 2.5 days. At the end of this time, we measured the
amount of long-chain ACs released from the nerves into the
culture media. Whereas Ctrl nerves released very low levels of
long-chain ACs into the surrounding media, Tfam-SCKO nerves
secreted 35-fold more long-chain ACs (primarily C16 and C18;
Figure 6D). Remarkably, the buildup of long-chain ACs fromNeuron 77, 886–898, March 6, 2013 ª2013 Elsevier Inc. 891
Figure 5. Abnormal Lipid Metabolism Secondary to Mitochondrial
Dysfunction Results in Depletion of Myelin Lipid Components and
Disrupts Axon–SC Interactions in Tfam-SCKO Nerves
(A and B) Lipidomic analysis reveals an early and significant depletion of two
key myelin lipid components, CBs (A) and STs (B), in 2-month-old Tfam-SCKO
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toz2 mM within 2.5 days.
We next assessed the ability of ACs to disrupt axonal
membrane properties and ion homeostasis. We specifically
focused on the effect of ACs on axonal calcium levels (Ca2+)
because long-chain ACs have been shown to alter Ca2+ homeo-
stasis in cardiac muscle (Yamada et al., 2000). Ca2+ is also
important for axonal integrity and function: intra-axonal Ca2+
elevation often leads to severe axon degeneration (George
et al., 1995), and its homeostasis is disrupted in peripheral
neuropathies (Fernyhough et al., 2010). Acute application of
palmitoyl-carnitine (PC), one of the most highly increased AC
species in Tfam-SCKO nerves, caused a significant elevation
of intracellular Ca2+ in cultured dorsal root ganglion (DRG)
neurons loaded with the calcium dye Fluo-4 (Figures 6E and
6F). This rise in intracellular Ca2+ took place within minutes after
exposure to AC, was dose dependent, and was specific to ACs;
application of the corresponding free fatty acid at the same
concentrations exerted no comparable effect (Figures 6E
and 6F). The acute influx of Ca2+ after addition of PC also caused
significant axonal blebbing (Figures 6E and 6G), which when
severe enough results in axonal degeneration.
Finally, we explored the long-term effect of chronic exposure
to moderate levels of ACs on axonal stability, because this
more likely recapitulates the situation in vivo. For these experi-
ments, we applied 25 mM PC onto DRG neurons daily for up to
9 days. This concentration caused no immediate axonal degen-
eration when applied acutely and was close to the range of
long-chain ACs released from a single Tfam-SCKO nerve cul-
tured as an explant (Figure 6D). Interestingly, the axons were
able to withstand exposure to 25 mM PC for up to 4 days. Afterversus Ctrl nerves. N = 5 mice per genotype. Error bars represent SEM;
*p < 0.05.
(C and D) Immunostaining of nodal architecture in 2-month-old Ctrl and Tfam-
SCKO nerves with antibodies against nodal (Nav1.6; C), paranodal (Caspr;
C and D), and juxtaparanodal (Kv1.2; D) markers shows normal clustering of
voltage-gated sodium channels (Nav1.6; C) but aberrant localization or loss of
voltage-gated potassium channel clusters (Kv1.2; D) around a significant
number of nodes following CB and ST depletion. Asterisks mark missing Kv1.2
clusters (D). Scale bar, 50 mm.
(E) Quantification of the number of nodes in 2-month-old Ctrl and Tfam-SCKO
nerves with intact Kv1.2 clusters (both) or with missing Kv1.2 clusters at either
one (half) or both sides of the node (none) as visualized in (D) confirms
disruption of ion channel clustering in Tfam-SCKO versus Ctrl nerves following
reductions in myelin-lipid components. N = 3 mice per genotype at each age.
Error bars represent SEM; *p < 0.05.
(F) Longitudinal electron micrographs from 2-month-old Tfam-SCKO sciatic
nerves show enlarged nodal gaps compared with Ctrls (segment line), indi-
cating abnormal axo-glial contacts around the nodes of Ranvier. N, node;
P, paranode; arrowheads, paranodal loops. Scale bar, 2 mm.
(G) Cross-sectional electron micrographs from 2-month-old Tfam-SCKO
sciatic nerves display a significant number of axons that have pulled away from
their myelin ensheathments (asterisks) compared with Ctrls, indicating dis-
rupted axo-glial adhesion in Tfam-SCKOs following CB and ST depletion.
Scale bar, 2 mm.
(H and I) Immunoblot analysis (H) and quantification (I) of 2-month-old nerves
reveal that ST and CB depletion precedes any decrease in expression of nerve
MBP, making lipid depletion a potential driver of the later demyelination. N = 3
mice per genotype. Error bars represent SEM.
See also Figure S2.
Figure 6. SC Accumulation and Release of AC
Fatty Acid b-Oxidation Intermediates Sec-
ondary to Mitochondrial Dysfunction Disrupts
Axonal Calcium Homeostasis and Stability
(A and B) Lipidomic analysis shows a significant
accumulation of long-chain ACs (total; A) that affects
most long-chain molecular species (B) in 2-month-
old Tfam-SCKO versus Ctrl nerves. N = 5 mice per
genotype. Error bars represent SEM; *p < 0.05.
(C) Diagram depicting fatty acid b-oxidation in the
mitochondria. Long-chain fatty acids are converted
to ACs to be shuttled into the mitochondrial matrix,
the site of b-oxidation, where they are oxidized
through repeated cycles of four enzymatic reactions.
Red text indicates the altered ratio of NAD/NADH+
in Tfam-SCKO nerves. Red stars indicate lipid in-
termediates accumulating in Tfam-SCKO nerves
following mitochondrial dysfunction. Cpt1 and Cpt2,
carnitine palmitoyltransferase 1 and 2; T outer, long-
chain fatty acid transporter; T inner, carnitine-AC
translocase; Co-Ash, coenzyme A.
(D) Explanted 2-month-old Tfam-SCKO nerves,
but not Ctrl nerves, release long-chain ACs into
surrounding culture media as measured by mass
spectrometry. N = 6 mice per genotype. Error bars
represent SEM; *p < 0.05.
(E) Images depicting increased fluorescence inten-
sity of the Ca2+ dye Fluo-4 after acute (30 min)
application of PC, an AC species that is highly
increased in Tfam-SCKO nerves, shows that this lipid
intermediate can disrupt axonal calcium homeo-
stasis. Note that similar changes were not seen when
the corresponding free fatty acid (palmitate [P]) was
applied. Scale bar, 100 mm.
(F and G) Quantification of the effect of PC on Fluo-4
intensity (F) and Ca2+ blebbing (G) shows that the
effect of this lipid intermediate on axonal calcium is
dose dependent and specific to ACs; application
of the corresponding free fatty acid at the same
concentrations exerted no comparable effect. N =
triplicate wells from one out of three representative
experiments. Error bars represent SEM; *p < 0.05.
(H) Images depicting a progressive increase in axonal
degeneration following chronic application of 25 mM
PC for 9 days. Scale bar, 100 mm.
(I) Quantification of axonal degeneration after chronic
treatment with 25 mM PC shows a significant,
progressive increase in the axon degeneration index.
N = 3 independent experiments with four to six wells
per condition. Error bars represent SEM; *p < 0.05.
See also Figure S3.
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Figure 7. Altered SC Lipid Metabolism
Accompanied by the Toxic Accumulation of
Lipid Intermediates Induces Axonal Degen-
eration and Demyelination in Mitochondria-
Related Peripheral Neuropathies
Diagram describing the proposed model for how
activation of a maladaptive ISR as well as a shift
in lipid metabolism away from lipid synthesis
and toward lipid oxidation secondary to SC mito-
chondrial dysfunction may contribute to pathology
in peripheral neuropathies.
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and axonal degeneration followed soon thereafter and progres-
sively worsened (Figures 6H and 6I). These results demonstrate
that the long-chain ACs that accumulate in SCs following mito-
chondrial dysfunction can be released out of these glia onto
the surrounding axons. Moreover, exposure of axons to long-
chain ACs can disrupt axonal membrane properties and ion
homeostasis, compromising axonal stability over time. Together,
our findings suggest that depletion of myelin lipid components
and accumulation of toxic lipid intermediates in SCs with
dysfunctional mitochondria are underlying pathological mecha-
nisms in peripheral neuropathies.
DISCUSSION
In this study we used a recently developed mouse model (Viader
et al., 2011) to identify the main disease processes in SCs that
contribute to the pathology of mitochondria-related peripheral
neuropathies. We show that respiratory-chain deficiency in
SCs activates a maladaptive ISR through the phosphorylation
of eIF2a by HRI kinase. Moreover, we demonstrate that mito-
chondrial dysfunction induces the remodeling of SC lipid metab-
olism away from synthesis and toward oxidation. This shift in
lipid metabolism results in the depletion of important lipid myelin
components, which initially disrupts axo-glial interactions and is
a likely driver of subsequent demyelination in mitochondria-
related neuropathies. Finally, we propose amechanism bywhich
lipid abnormalities in SCs can exacerbate axonal loss in
peripheral neuropathies through the release of toxic long-chain
ACs (Figure 7). Activation of a maladaptive ISR and disruption
of SC lipid metabolism homeostasis secondary to mitochondrial
dysfunction are thus critical underlying pathological mecha-
nisms in peripheral neuropathies.
Mitochondrial dysfunction is a common cause of peripheral
neuropathies. We recently generated the first mouse model
(Tfam-SCKOs) that is useful for directly interrogating the contri-
bution of SC mitochondrial derangements to peripheral neurop-
athy by disrupting mitochondria specifically in these glia (Viader
et al., 2011). Interestingly, SC mitochondrial deficits in Tfam-
SCKO mice did not affect the survival of these glia, and instead894 Neuron 77, 886–898, March 6, 2013 ª2013 Elsevier Inc.resulted in a severe, progressive neurop-
athy characterized by extensive axonal
degeneration that recapitulated critical
features of human peripheral nerve dis-
eases (Viader et al., 2011). These resultsshowed that normal mitochondrial function in SCs is essential
for maintaining the axo-glial interactions that are required
for long-term support of axons and normal peripheral nerve
function. Moreover, our study demonstrates that SC mitochon-
dria are underappreciated contributors to the abnormalities
observed in neuropathies, since key pathological features com-
monly encountered in human peripheral nerve disease could
be explained by SC-specific mitochondrial dysfunction. There-
fore, investigators seeking to develop effective therapies for
peripheral neuropathies will need to address the mechanisms
by which SCs contribute to disease progression, and, as shown
above, Tfam-SCKO mice could be particularly useful in this
undertaking.
Our examination of Tfam-SCKO mice uncovered the activa-
tion of the ISR in Tfam-deficient SCs secondary to mitochondrial
dysfunction. The ISR is a conserved, stress-activated gene-
expression program centered on phosphorylation of eIF2a
(Dalton et al., 2012). Activation of this program is meant to
promote a cellular stress-resistant state by global attenuation
of protein synthesis, which reduces the ER load and diverts
amino acids from energetically costly protein synthesis to other
metabolic pathways (Walter and Ron, 2011). Activation of the
ISR in SCs, however, has previously been shown to be particu-
larly maladaptive. In a model of CMT caused by mutations to
myelin P0, accumulation of mutant P0 in the ER activated the
ISR as part of a UPR (Pennuto et al., 2008). Importantly, blocking
the induction of this pathway prevented the behavioral and
pathological presentations of this disease model. This and other
studies led to the notion that UPR-mediated activation of the ISR
in SCs contributes to the pathology in myelin-related neuropa-
thies (Lin and Popko, 2009). Here, we show that defects in mito-
chondrial respiration can also induce eIF2a phosphorylation and
ISR through the actions of HRI kinase independently of ER
stress. The maladaptive activation of the ISR in SCs through
distinct eIF2a kinases that respond to diverse stressors (e.g.,
HRI to mitochondrial dysfunction, and PERK to ER stress) may
thus be a central pathological mechanism common to diverse
forms of neuropathy. This is highlighted by the fact that chemo-
therapeutic agents that cause neuropathy also activate the ISR
in cultured cells (Gately et al., 1996).
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remodeling of SC lipid metabolism away from synthesis and
toward oxidation following mitochondrial deficits. Lipids play
a crucial role in the normal biology of SCs (Chrast et al., 2011),
and the observed early shift in the lipid metabolism of Tfam-
SCKO nerves is likely to participate in the subsequent neurop-
athy phenotype of these mice. The depletion of CBs and STs
from Tfam-deficient SCs, which together represent almost
30% of all myelin lipid content (Garbay et al., 2000), could
account for the prominent demyelinating phenotype apparent
in late stages of disease in Tfam-SCKO mice (Figure 1; Viader
et al., 2011). Moreover, given the central role of STs and CBs
in maintaining axon-supportive axon–glia contacts (Figure 5;
Dupree et al., 1998; Hoshi et al., 2007), their depletion could
also drive some of the axon loss in Tfam-SCKO nerves. This
axonal degeneration is likely exacerbated by the accumulation
of ACs in Tfam-SCKO nerves following mitochondrial dysfunc-
tion. Accordingly, long-chain ACs accumulating in SCs could
be released onto surrounding axons, where they could disrupt
axon membrane properties and induce axon degeneration
(Figure 6). These results are consistent with presentations of
peripheral neuropathy in patients with genetic defects in fatty
acid b-oxidation that lead to a buildup of ACs (Schaefer et al.,
1996; Tyni and Pihko, 1999). Together, our results suggest
that alterations in SC lipid metabolism, particularly defects in
b-oxidation, may be central pathological mechanisms of mito-
chondrial-related neuropathies.
Interestingly, although the precise downstream cellular
processes initiated by the ISR that are maladaptive to SCs are
unclear, recent reports have linked activation of this pathway
to altered lipidmetabolism. ISR induction is reported to decrease
expression of lipid biosynthetic genes (Harding et al., 2005), alter
intermediate lipid metabolism (Oyadomari et al., 2008), and
cause an overall shift away from lipogenesis and toward oxida-
tion (Qi et al., 2006). The results described above are consistent
with a decreased shunting of fatty acids toward new lipid
synthesis and a concomitant increase in fatty acid oxidation in
the nerves of Tfam-SCKO mice. The pathological remodeling
of SC lipid metabolism in Tfam-SCKO mice could thus be
mediated, at least in part, by the maladaptive HRI-dependent
activation of the ISR following respiratory-chain deficiency in
SC mitochondria. The interaction between these two main
neuropathy-driving processes in Tfam-SCKO nerves highlights
their potential as therapeutic targets. Moreover, it suggests
that the pathological lipid metabolic abnormalities identified
here in the context of SCmitochondrial deficits could be relevant
to a number of other neuropathies and encephalopathies that
present with ISR activation, such as CMT disease, Pelizaeus-
Merzbacher disease, vanishing white matter disease, and mul-
tiple sclerosis (Lin and Popko, 2009).
Metabolic support of axons by ensheathing cells has been
postulated to be critical to the ability of both central (oligoden-
drocytes [OLs]) and peripheral (SCs) glia to maintain axonal
stability and function (Nave and Trapp, 2008). For example,
SCs andOLs could support axons through the transfer of metab-
olites, as is the case for CNS neurons and astrocytes (Benarroch,
2005). A recent report (Fu¨nfschilling et al., 2012) showed that
mitochondrial deficits in OLs provoked an increased relianceon glycolysis by these glia to meet their energy requirements.
Since these mice did not develop encephalopathy, the glycolytic
shift presumably preserved oligodendrocyte viability as well as
their ability to generate the metabolic intermediates necessary
to support ensheathed axons. Following mitochondrial dysfunc-
tion in Tfam-SCKOs, we observed similar metabolic adaptations
in SCs, which helped maintain their cellular energy levels and
ensure their long-term survival (Figures 1 and S1; Viader et al.,
2011). In the case of SCs, however, increased glycolysis and
residual mitochondrial function were apparently insufficient for
preservation of peripheral axons. These results suggest that
activation of maladaptive cellular pathways and generation of
toxic lipid species rather than loss of metabolic support may
ultimately account for much of the SC-mediated pathology
observed in mitochondria-related peripheral neuropathies.
In summary, the use of Tfam-SCKO mice, a model of neurop-
athy secondary to mitochondrial dysfunction, enabled us to
examine the mechanisms by which deficits in mitochondrial
metabolism in SCs specifically contribute to peripheral nerve
diseases. Our work demonstrates that mitochondrial deficits
activate a maladaptive stress response in SCs and cause a shift
in the lipid metabolism of these glial cells. We provide evidence
that the resulting early depletion of important lipid myelin
components, as well as the accumulation and release of toxic
lipid intermediates from SCs, drives the pathology observed in
Tfam-SCKO mice. New therapeutic strategies that prevent
depletion of lipids that support axo-glial interactions and block
accumulation of fatty acid intermediates with marked axonal
toxicity may be useful for treating patients with diabetic neurop-
athy and other mitochondria-related peripheral nerve disorders.
EXPERIMENTAL PROCEDURES
Mating of Transgenic Animals
All animal experiments were carried out in compliance with institutional animal
protocols. Tfam-SCKO mice (P0-Cre
/+, TfamloxP/loxP) and Ctrl littermates
(P0-Cre
/, TfamloxP/loxP) were generated by crossing TfamloxP/loxP mice
(Larsson et al., 1998) to P0-Cremice (Feltri et al., 1999). Mating and genotyping
were carried out as previously described (Viader et al., 2011).
Nerve Histology and Morphometry
For nerve histology and morphometry, sciatic nerves from Ctrl and Tfam-
SCKO mice of different ages were embedded in 100% epoxy. Sections
(1 mm thick) were prepared and stained with toluidine blue for light microscopy,
and ultrathin sections (100 nm thick) were prepared for electron microscopy.
All of the nerves underwent qualitative assessment of neural architecture
followed by detailed histomorphometric analysis carried out as previously
described (Hunter et al., 2007). Frozen sections or teased nerve fibers were
used for immunohistochemical analysis of sciatic nerves. Following incubation
with the appropriate primary and secondary antibodies, all slides were
mounted for microscopic visualization using an upright epifluorescent micro-
scope (Nikon 80i; CoolSnapES camera). Images were processed using
MetaMorph and ImageJ (see Supplemental Experimental Procedures for
details).
Metabolite Measurements
For ATP, ADP, AMP, and lactate measurements, sciatic nerves were extracted
with perchloric acid and assayed by high-performance liquid chromatography.
Elution peaks were compared with standards for identification and quantifica-
tion, and levels were normalized to tissue weight (see Supplemental Experi-
mental Procedures for details). EC was defined as ([ATP]+1/2[ADP])/([ATP]+
[ADP]+[AMP]). Lactate levels were determined spectrophotometrically asNeuron 77, 886–898, March 6, 2013 ª2013 Elsevier Inc. 895
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NAD+/NADH ratio were determined using a CycLex NAD+/NADH colorimetric
assay kit (MBL International) according to the manufacturer’s protocol.
Western Blotting
For western blotting, sciatic nerves were homogenized by sonication, and
proteins were separated by SDS-PAGE and transferred to a polyvinylidene
difluoride (PVDF) membrane (Millipore). Membranes were then blocked and
incubated overnight with the appropriate primary antibody (see Supplemental
Experimental Procedures for details). Following incubation with secondary
antibodies conjugated to horseradish peroxidase (HRP; GE Healthcare), the
membranes were developed with SuperSignal West Dura substrate (Pierce).
The optical density of the signals was determined using ImageJ.
RNA Preparation and qRT-PCR
Total RNA was isolated after homogenization (for sciatic nerves) or lysis (for
cultured SCs) in Qiazol lysis reagent (QIAGEN) using a miRNeasy Minikit
(QIAGEN) according to the manufacturer’s protocol. RNA concentration was
quantified using an ND-1000 spectrophotometer (Nanodrop Technologies).
mRNA was reverse transcribed from 100 ng of total RNA using qScript
cDNA SuperMix (Quanta Biosciences). mRNA qRT-PCR was performed using
a SYBR green-based detection system on a 7900 HT Sequence Detector
instrument (Applied Biosystems) as described previously (Nagarajan et al.,
2001). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression
was used to normalize samples and obtain relative expression values that
were used to calculate percent changes. See Supplemental Experimental
Procedures for primer sequences.
Microarray and Computational Analysis
Total RNA samples were prepared by isolating and pooling RNA from at least
three different 2-month-old Tfam-SCKO and Ctrl mice. Replicates were
prepared entirely independently from two separate pools of at least three
animals each, and two replicates were used. WG-6 v2.0 Expression BeadChip
arrays (Illumina) were used according to the manufacturer’s recommendations
(see Supplemental Experimental Procedures for details). To analyze the result-
ing data, we performed a two-class unpaired significance analysis of micro-
arrays (SAM) analysis. Differentially expressed genes with at least 2-fold
differential regulation between Tfam-SCKO andCtrl nerves at a false discovery
rate (FDR) of 0.5% were selected for further analysis. Gene enrichment of the
metabolic pathway was examined using GeneGO (Genego).
Nerve Sample Lipid Extract Preparation and Analysis by
Multidimensional Mass-Spectrometry-Based Shotgun Lipidomics
Lipid extraction of nerve samples was performed essentially as described
previously (Han et al., 2008). A triple-quadrupole mass spectrometer (TSQ
Quantum Ultra Plus; Thermo Fisher) equipped with an automated nanospray
apparatus (Nanomate HD; Advion Bioscience Ltd.) and Xcalibur system
software together with building block analyses (Yang et al., 2009) were utilized
to identify each individual lipid species in a lipid class (see Supplemental
Experimental Procedures for details).
Primary SC Cultures and In Vitro ISR Induction
Primary rat SCswere cultured from sciatic nerves of postnatal day 1–3 rat pups
as previously described (Nagarajan et al., 2001). For SC in vitro ISR induction
assays, SCs were initially seeded onto collagen-coated 24-well plates
(75,000 cells/well) in 10% fetal bovine serum (FBS)-Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 2 mM forskolin and 20 mg/ml of
bovine pituitary extract. The cells were switched 48 hr later to 1% FBS-
DMEM for 2 days to stop proliferation. At this point, the SCs were treated
with either vehicle, 5 mM CCCP, 2.5 mM oligomycin, 10 mM antimycin, or
1 mM tunicamycin. RNA and protein were isolated 24 hr later. The reported
results are from duplicate wells from at least three independent assays.
eIF2aKinase Small Hairpin RNA Knockdown in 3T3 Cells and In Vitro
ISR Induction
NIH 3T3 cells were infected with lentivirus expressing small hairpin RNA
(shRNA) to one of four eIF2a kinases (HRI, PKR, PERK, and GCN2; see896 Neuron 77, 886–898, March 6, 2013 ª2013 Elsevier Inc.Supplemental Experimental Procedures for details). The infected cells were
selected by growth in puromycin for 5 days, and cell populations with signifi-
cant knockdown of each kinase were obtained and frozen as polyclonal
populations. The polyclonal populations of cells were then seeded onto
24-well plates (50,000 cells/well) in 10% FBS-DMEM. Sixteen hours after
seeding, the cells were treated with either vehicle or 5 mM CCCP for 3 hr
(for p-eIF2a induction) or 6 hr (for DDIT3/CHOP induction). The cells were
then harvested for western blot analysis.
AC Release Measurements
Tomeasure the ability of Tfam-deficient SCs to secrete long-chain ACs, nerves
were explanted from Tfam-SCKO and Ctrl mice and maintained in 100 ml of
10% FBS supplemented with 2 mM L-glutamine and 100 ng/ml of nerve
growth factor for 2.5 days. At this time, the medium was collected and imme-
diately frozen in liquid nitrogen. Themediumwas then analyzed for AC species
content (C2–C18 saturated, unsaturated, and hydroxylated) as butyl esters by
direct flow injection and precursor ion scanning on an API 3200 LC-MS/MS
system (Applied Biosystems). Quantitation was achieved using a cocktail of
internal standards. Concentrations were normalized to tissue weight.
DRG Neuron Culture and Fluo-4 Imaging
Mouse DRG neurons isolated from E12 embryos were seeded onto 24-well or
96-well cell culture plates coated with poly-D-lysine (Sigma) and laminin
(Invitrogen), and all experiments were carried out 5–6 days after seeding. For
calcium imaging experiments, neurons were incubated with the calcium
indicator Fluo-4 AM (2 mM; Invitrogen) and neurons were then treated with
vehicle, PC (Sigma), or palmitate (Sigma) at the appropriate concentrations.
Phase and fluorescence images were acquired every 15 min for up to 6 hr
using an Operetta imaging system equipped with an environmental chamber
(Perkin Elmer), and automated image analysis was carried out using ImageJ.
To examine the effect of chronic AC exposure, DRG neurons were treated daily
for up to 9 days with vehicle or with PC at the appropriate concentration (see
Supplemental Experimental Procedures for details).
Statistical Analysis
All values are expressed as mean ± SEM, and, if no units are specified, are
expressed as percent of control. If not stated otherwise, p values were deter-
mined by unpaired, two-tailed Student’s t test. All statistical analyses were
performed using Microsoft Excel 2007.
ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number for the microarray
data reported in this paper is GSE44605.
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